Intelligence · Clinical Development
Pipeline search results
Programs matching “tislelizumab” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 50 pipeline programs matching "tislelizumab" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Subcutaneous Tislelizumab
BEONE MEDICINES AUS PTY LTD
Metastatic Gastric Adenocarcinoma
1 trial -
Tislelizumab
BEONE MEDICINES AUS PTY LTD
Advanced Malignancies
1 trial -
Tislelizumab
BeiGene
Non-small Cell Lung Cancer
2 trials -
Tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Locally Advanced Rectal Carcinoma
1 trial -
Tislelizumab
BEONE MEDICINES AUS PTY LTD
Non Small Cell Lung Cancer
4 trials -
Tislelizumab
BeiGene
Recurrent or Metastatic Nasopharyngeal Cancer
1 trial -
Tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colonic Neoplasms
1 trial -
Tislelizumab
The First People's Hospital of Lianyungang
Rectal Neoplasms
1 trial -
Tislelizumab
BEONE MEDICINES AUS PTY LTD
Urothelial Carcinoma
1 trial -
Tislelizumab
BEONE MEDICINES AUS PTY LTD
Classical Hodgkin Lymphoma
1 trial -
Tislelizumab
BEONE MEDICINES AUS PTY LTD
Esophageal Squamous Cell Carcinoma (ESCC)
1 trial -
Tislelizumab + SOX Chemotherapy
The First People's Hospital of Lianyungang
Gastric Cancer Stage III
1 trial -
Tislelizumab（neoadjuvant）
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Head and Neck Squamous Cell Carcinomas
1 trial -
Brentuximab Vedotin in Combination with Tislelizumab
Takeda
NK/T Cell Lymphoma Nos
1 trial -
CCRT with Maintenance Tislelizumab and Metronomic Capecitabine
BEONE MEDICINES AUS PTY LTD
Nasopharyngeal Carcinoma
1 trial -
Chidamide + Tislelizumab + chemotherapy (CapeOX )
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colon Adenocarcinoma
1 trial -
Experimental: tislelizumab+anlotinib
The First People's Hospital of Lianyungang
Thymic Carcinoma
1 trial -
HAIC + Tislelizumab +lenvatinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma (HCC)
1 trial -
IMX-110 combined with Tislelizumab
Immix Biopharma
Advanced Solid Tumor
1 trial -
SBRT combined with Nimotuzumab followed by Tislelizumab
The First People's Hospital of Lianyungang
Nasopharyngeal Cancinoma (NPC)
1 trial -
SBRT combined with Tislelizumab followed by Tislelizumab
Zibo Municipal Hospital
NSCLC
1 trial -
Sacituzumab Tirumotecan in combination with tislelizumab
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
TISLELIZUMAB
Fondazione Telethon ETS
Hodgkin lymphoma
1 trial -
Tislelizumab
BeiGene
Cervical Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.